P097 Preliminary experience with ihtOBTURA®: a novel non-adhesive liquid embolic agent, with post embolization loss of radiopacity, for the endovascular treatment of brain arteriovenous malformations. claridad study

<h3>Introduction</h3> ihtOBTURA® (IBERHOSPITEX, Llica de Ball, Spain) is a revolutionary non-adhesive liquid embolic agent, composed by EVOH copolymer and an iodinated compound, dissolved in DMSO <h3>Aim of Study</h3> To report a Preliminary Experience with ihtOBTURA®: A Novel Non-Adhesive Liquid Embolic Agent, with post embolization loss of radiopacity, for the Endovascular Treatment of Brain Arteriovenous Malformations <h3>Methods</h3> We performed a prospective longitudinal single center study, from November 10, 2021, to September 10, 2022. 42 consecutive patients with brain AVMs, were treated by endovascular way. A total of 102 endovascular procedures were performed with ihtOBTURA®. There were 23 males and 19 females with a mean age of 37.38 years. The most common clinical presentation was intracranial hemorrhage in 35 (83.33%) patients. According to the Spetzler-Martin scale, 25 (59,52%) AVMs were grades IV; 13 (30,95%) AVMs, grade III; and 4 (9,52) AVMs, grades II <h3>Results</h3> Complete occlusion was achieved in 26/28 patients (93%) during the study interval, and in 61.90% (26/42) in the entire patient cohort. The 14 remaining patients are scheduled for further EVT. Stability of angiographic occlusion was confirmed in all 26 patients by a control angiogram at 6 months. Mean volume reduction was 80,79% per patients. whereas an average of 7.2 mL of ihtOBTURA® was used per patient. Disabling Permanent Neurological Deficits included 1 case of postinterventional hemorrhage and there were 1 procedure-related death. <h3>Conclusion</h3> ihtOBTURA® is a safe and effective new non-adhesive liquid embolic agent, with innovative properties that can improve results on AVMs treatment. <h3>Disclosure of Interest</h3> no.